GlassScriptPhysician profile
Charles Andrew Chacko
NPI 1518301019
$18,783.84
in general payments reported to CMS, 2019-2025
39 companies · $2,491 in 2025
The $2,491 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $201 · 2021: $201 · 2022: $1,413 · 2023: $2,047 · 2024: $12K · 2025: $2,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $3,329 · Travel and Lodging: $1,312 · Honoraria: $200 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,255.00 |
| Food and Beverage | $3,329.29 |
| Travel and Lodging | $1,312.37 |
| Honoraria | $200.00 |
| Education | $190.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $8,439.65 | 2024 | Imfinzi, Calquence, Truqap |
| Daiichi Sankyo INC. | $2,811.70 | 2023-2025 | Datroway, Enhertu |
| Beigene USA, INC. | $909.45 | 2023-2024 | Brukinsa |
| Geron Corporation | $780.00 | 2025 | Rytelo |
| Abbvie INC. | $653.12 | 2023-2025 | Epkinly, Venclexta |
| Pfizer INC. | $466.95 | 2022-2024 | |
| Janssen Biotech, INC. | $438.12 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $431.68 | 2022-2024 | Opdivo, Opdualag |
| Kite Pharma, INC. | $319.36 | 2022-2023 | Yescarta |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $247.80 | 2019-2024 | |
| Incyte Corporation | $222.21 | 2021-2023 | Jakafi |
| Sobi, INC | $200.00 | 2024 | |
| Merck Sharp & Dohme LLC | $192.57 | 2020-2024 | Keytruda, Lynparza |
| Pharmacyclics LLC, An Abbvie Company | $171.69 | 2019-2023 | Imbruvica, Epkinly |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Andrew Chacko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.